阿扎那韦硫酸盐

5至<15公斤

每天一次200毫克（4包）

每天80毫克

15至<25公斤

每天一次250毫克（5包）

每天80毫克

≥25公斤且不能吞服胶囊

每天一次300毫克（6包）

每天一次100毫克

<15公斤

不推荐胶囊

15至<20公斤

每天一次150毫克

每天一次100毫克

20至<40公斤

每天一次200毫克

每天一次100毫克

≥40公斤

每天一次300毫克

每天一次100毫克

阿巴卡韦

No in vitro evidence of antagonistic antiretroviral effects with atazanavir ¹

对乙酰氨基酚

Pharmacokinetic interactions unlikely ^{1 238}

阿夫唑嗪

Possible increased alfuzosin concentrations; may result in hypotension ^{1 238 239}

Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

抗酸剂

Possible decreased atazanavir concentrations ^{1 238}

Administer ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir at least 2 hours before or 1–2 hours after antacids ^{1 200 238}

Antiarrhythmic agents (amiodarone, disopyramide, dofetilide, dronedarone, flecainide, systemic lidocaine, mexiletine, propafenone, quinidine)

Amiodarone, dofetilide, dronedarone, flecainide, systemic lidocaine, propafenone, quinidine: Possible increased antiarrhythmic agent concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir; potential for serious and/or life-threatening effects ^{1 200 238 239}

Disopyramide, mexiletine: Possible increased antiarrhythmic agent concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Disopyramide, dofetilide, flecainide, systemic lidocaine, mexiletine, propafenone, quinidine: Use concomitantly with caution; monitor serum concentrations of antiarrhythmic agent ^{1 200 238 239}

Amiodarone: Experts state monitor for amiodarone toxicity if used with ritonavir-boosted or cobicistat-boosted atazanavir; ²⁰⁰ consider monitoring ECG and amiodarone concentrations ²⁰⁰

Dronedarone: Concomitant use with cobicistat-boosted atazanavir contraindicated; ^{238 239} experts state concomitant use with ritonavir-boosted or unboosted atazanavir also contraindicated ²⁰⁰

Anticoagulants, oral (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin)

Apixaban: Increased apixaban concentrations expected ^{200 238}

Dabigatran: Possible increased dabigatran concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{200 238}

Edoxaban: Increased edoxaban concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ²⁰⁰

Rivaroxaban: Possible increased rivaroxaban concentrations; may increase bleeding risk ^{200 238 239}

Warfarin: Potential for increased or decreased warfarin concentrations and serious and/or life-threatening bleeding episodes if used with ritonavir-boosted or unboosted atazanavir; ^{1 200} effect of cobicistat-boosted atazanavir on warfarin concentrations unknown ^{200 238 239}

Apixaban, edoxaban, rivaroxaban: Avoid concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Dabigatran: Concomitant use with ritonavir-boosted or cobicistat-boosted atazanavir not recommended in certain patients with renal impairment; ^{200 238} experts state avoid concomitant use in those with Cl _cr <50 mL/minute ²⁰⁰

Warfarin: Monitor INR if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 200 238 239} (especially when initiating or discontinuing atazanavir) and adjust warfarin dosage accordingly; ²⁰⁰ if ritonavir-boosted atazanavir switched to cobicistat-boosted atazanavir, effect on warfarin concentrations not expected to be equivalent ²⁰⁰

Anticonvulsants (carbamazepine, eslicarbazepine, ethosuximide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin)

Carbamazepine: Possible decreased atazanavir concentrations and increased carbamazepine concentrations if used with ritonavir-boosted atazanavir; ^{1 200} possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir; ^{238 239} decreased atazanavir concentrations if used with unboosted atazanavir ^{1 200}

Eslicarbazepine: Possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir ²³⁸

Ethosuximide: Possible increased ethosuximide concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Lamotrigine: Decreased lamotrigine concentrations and AUC if used with ritonavir-boosted atazanavir; ^{1 200} effect of cobicistat-boosted atazanavir on lamotrigine concentrations unknown; ^{200 238} interaction not expected with unboosted atazanavir ^{1 200}

Oxcarbazepine: Possible decreased atazanavir and cobicistat concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Phenobarbital, phenytoin: Possible decreased concentrations of atazanavir and the anticonvulsant if used with ritonavir-boosted atazanavir; ^{1 200} possible decreased atazanavir and cobicistat concentrations may result in loss of therapeutic effect and development of resistance if used with cobicistat-boosted atazanavir; ^{238 239} decreased atazanavir concentrations if used with unboosted atazanavir ^{1 200}

Carbamazepine: Concomitant use with unboosted atazanavir not recommended; ^{1 200} consider alternative anticonvulsant in patients receiving ritonavir-boosted atazanavir; ²⁰⁰ if used with ritonavir-boosted atazanavir, consider that reduced anticonvulsant dosage may be needed, monitor serum concentrations of both drugs, assess virologic response; ^{200 238 239} concomitant use with cobicistat-boosted atazanavir contraindicated ^{200 238}

Eslicarbazepine: Consider alternative anticonvulsant or alternative antiretroviral; ²³⁸ if used concomitantly with cobicistat-boosted atazanavir, monitor for lack or loss of antiretroviral response ²³⁸

Ethosuximide: Monitor for ethosuximide toxicities if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Lamotrigine: Increased lamotrigine dosage may be needed and consider monitoring lamotrigine concentrations if used with ritonavir-boosted atazanavir or consider alternative anticonvulsant; ^{1 200} monitor lamotrigine concentrations if used with cobicistat-boosted atazanavir or consider alternative anticonvulsant; ^{200 238} dosage adjustments not needed if used with unboosted atazanavir ^{1 200}

Oxcarbazepine: Consider alternative anticonvulsant or alternative antiretroviral; ^{238 239} if used concomitantly with cobicistat-boosted atazanavir, monitor for lack or loss of antiretroviral response ^{238 239}

Phenobarbital, phenytoin: Concomitant use with unboosted atazanavir not recommended; ^{1 200} consider alternative anticonvulsants in patients receiving ritonavir-boosted atazanavir; ²⁰⁰ if used with ritonavir-boosted atazanavir, consider that anticonvulsant dosage adjustment may be needed, monitor serum concentrations of both drugs, and assess virologic response; ²⁰⁰ concomitant use with cobicistat-boosted atazanavir contraindicated ^{200 238}

抗真菌剂，唑类

Fluconazole: No clinically important pharmacokinetic interactions with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238}

Isavuconazonium (prodrug of isavuconazole): Possible increased isavuconazole concentrations and altered atazanavir concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Itraconazole: Possible increased itraconazole, atazanavir, and cobicistat concentrations if used with ritonavir-boosted , cobicistat-boosted, or unboosted atazanavir ^{1 200 238 239}

Ketoconazole: No clinically important pharmacokinetic interactions with unboosted atazanavir; ¹ possible increased ketoconazole, atazanavir, and cobicistat concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238 239}

Posaconazole: Increased atazanavir concentrations if used with ritonavir-boosted or unboosted atazanavir; ^{32 200} possible pharmacokinetic interactions if used with cobicistat-boosted atazanavir ²⁰⁰

Voriconazole: Decreased atazanavir and voriconazole concentrations if used with ritonavir-boosted atazanavir in patients with functional CYP2C19 allele and decreased atazanavir concentrations and increased voriconazole concentrations in those without functional CYP2C19 allele; ^{1 200} effect of cobicistat-boosted atazanavir on voriconazole concentrations unknown; ^{200 238 239} possible altered atazanavir and voriconazole concentrations if used with unboosted atazanavir ^{1 200}

Fluconazole: Dosage adjustments not needed if used with ritonavir-boosted or cobicistat-boosted atazanavir ²⁰⁰

Isavuconazonium: Monitor for atazanavir-associated adverse effects and virologic efficacy if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir; ²⁰⁰ consider monitoring isavuconazole concentrations ²⁰⁰

Itraconazole: Consider monitoring itraconazole concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir and adjust itraconazole dosage accordingly; ²⁰⁰ caution advised if itraconazole dosage >200 mg daily is used with ritonavir-boosted atazanavir; ¹ specific dosage recommendations not available for use with cobicistat-boosted atazanavir; ^{238 239} some experts state itraconazole dosages >200 mg daily not recommended with ritonavir-boosted or cobicistat-boosted atazanavir unless itraconazole concentrations used to guide antifungal dosage ²⁰⁰

Ketoconazole: Caution advised if ketoconazole dosage >200 mg daily used with ritonavir-boosted atazanavir; ¹ specific dosage recommendations not available for use with cobicistat-boosted atazanavir ^{238 239}

Posaconazole: Monitor for atazanavir-associated adverse effects if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{32 200}

Voriconazole: Do not use with ritonavir-boosted or cobicistat-boosted atazanavir unless potential benefits outweigh risks; ^{1 200 238 239} if used with ritonavir-boosted or cobicistat-boosted atazanavir, monitor for voriconazole-associated adverse effects and loss of voriconazole or atazanavir efficacy and consider monitoring voriconazole concentrations and adjusting voriconazole dosage accordingly; ^{1 200} if used with unboosted atazanavir, monitor for toxicities ²⁰⁰

Antimalarial agents

Fixed combination of atovaquone and proguanil (atovaquone/proguanil): Decreased atovaquone and proguanil concentrations if used with ritonavir-boosted atazanavir ²⁰⁰

Atovaquone/proguanil: Consider alternative antimalarial, if possible ²⁰⁰

Antimycobacterials (bedaquiline, rifabutin, rifampin, rifapentine)

Bedaquiline: Possible increased bedaquiline concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir; ²⁰⁰ clinical importance unknown

Rifabutin: Increased concentrations and AUC of rifabutin and its metabolite if used with ritonavir-boosted or unboosted atazanavir; ^{1 200} increased rifabutin concentrations expected if used with cobicistat-boosted atazanavir, but effects on atazanavir and cobicistat concentrations unknown ^{238 239}

Rifampin: Substantially decreased atazanavir concentrations; possible loss of virologic response and development of resistance ^{1 238}

Rifapentine: Possible decreased atazanavir concentrations with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir with loss of antiretroviral effect and development of resistance ^{1 200 238}

Bedaquiline: If potential benefits outweigh risks, use with ritonavir-boosted or cobicistat-boosted atazanavir with caution and monitor for QT _c interval prolongation and liver dysfunction ²⁰⁰

Rifabutin: If used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir, reduce rifabutin dosage to 150 mg once every other day or 3 times weekly; ^{1 200 238 239} some experts suggest rifabutin 150 mg once daily or 300 mg 3 times weekly; ²⁰⁰ monitor for rifabutin-associated adverse effects (eg, neutropenia, uveitis); ^{1 238 239} monitor for antimycobacterial response and consider therapeutic drug monitoring ²⁰⁰

Rifampin: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Rifapentine: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir not recommended ²⁰⁰

Antineoplastic agents (dasatinib, irinotecan, nilotinib, paclitaxel, vinblastine, vincristine)

Dasatinib, nilotinib: Possible increased antineoplastic concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Irinotecan: Possible interference with metabolism of irinotecan and increased risk of irinotecan toxicity if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Paclitaxel: Possible increased paclitaxel concentrations if used with unboosted atazanavir; ¹ clinically important interactions not expected if used with ritonavir-boosted atazanavir ¹

Vinblastine, vincristine: Possible increased antineoplastic concentrations if used with cobicistat-boosted atazanavir ^{238 239}

Dasatinib, nilotinib: If used with cobicistat-boosted atazanavir, decreased dosage of the antineoplastic may be needed ^{238 239}

Irinotecan: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Paclitaxel: Caution advised if used with unboosted atazanavir; ¹ concomitant use with cobicistat-boosted atazanavir not recommended ²³⁸

Vinblastine, vincristine: Monitor for adverse hematologic or GI effects if used with cobicistat-boosted atazanavir ²³⁸

Antipsychotics (lurasidone, perphenazine, pimozide, quetiapine, risperidone, thioridazine)

Lurasidone: Possible increased lurasidone concentrations if used with ritonavir-boosted or unboosted atazanavir; ^{1 238} potential for serious and/or life-threatening adverse effects if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{1 238}

Perphenazine, risperidone, thioridazine: Possible increased antipsychotic agent concentrations if used with ritonavir-boosted or cobicistat-boosted atazanavir ^{200 238 239}

Pimozide: Potential for serious and/or life-threatening effects (eg, cardiac arrhythmias) if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Quetiapine: Increased quetiapine concentrations expected if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 200 238 239}

Lurasidone: Concomitant use with ritonavir-boosted or cobicistat-boosted atazanavir contraindicated; ^{1 238} experts state do not use concomitantly with unboosted atazanavir; ²⁰⁰ if concomitant use with unboosted atazanavir necessary, reduce lurasidone dosage ¹

Perphenazine, risperidone, thioridazine: Decreased antipsychotic dosage may be needed if used with ritonavir-boosted or cobicistat-boosted atazanavir; ^{200 238 239} experts state initiate antipsychotic at lowest dosage, adjust maintenance dosage as needed, and monitor for antipsychotic-associated toxicities ²⁰⁰

Pimozide: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239}

Quetiapine: Consider alternative antiretroviral; ^{1 238 239} if ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir necessary in patient receiving stable quetiapine dosage, reduce quetiapine dosage to one-sixth of original dosage and monitor for quetiapine efficacy and adverse effects; ^{1 200 238 239} if quetiapine necessary in patient receiving ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir, experts state initiate using lowest quetiapine dosage and titrate as needed ²⁰⁰

Atovaquone

Ritonavir-boosted atazanavir: No effect on atovaquone concentrations ²⁰⁰

Ritonavir-boosted atazanavir: Dosage adjustments not needed ²⁰⁰

阿瓦那非

Possible increased avanafil concentrations and AUC ^{183 200 238 239}

Do not use concomitantly with ritonavir-boosted or cobicistat-boosted atazanavir; ^{183 200 238 239} experts state that unboosted atazanavir can be used if avanafil dosage does not exceed 50 mg once every 24 hours ²⁰⁰

Benzodiazepines

Alprazolam: Possible increased alprazolam concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ²⁰⁰

Clonazepam: Possible increased clonazepam concentrations if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Diazepam: Possible increased diazepam concentrations If used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{200 238 239}

Midazolam or triazolam: Possible increased concentrations of midazolam or triazolam and potential for serious and/or life-threatening effects (eg, prolonged or increased sedation or respiratory depression) if used with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir ^{1 238 239}

Lorazepam, oxazepam, temazepam: No data, but may have less potential for pharmacokinetic interactions with PIs compared with other benzodiazepines ²⁰⁰

Alprazolam: Consider alternative benzodiazepine with less potential for interactions (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Clonazepam: Clinical monitoring recommended if used with cobicistat-boosted atazanavir; ^{238 239} experts state consider alternative (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Diazepam: If used with cobicistat-boosted atazanavir, decreased diazepam dosage may be needed and monitor for adverse effects; ^{238 239} experts state consider alternative (eg, lorazepam, oxazepam, temazepam) ²⁰⁰

Oral midazolam or triazolam: Concomitant use with ritonavir-boosted , cobicistat-boosted , or unboosted atazanavir contraindicated ^{1 238 239</}

已知共有478种药物与阿扎那韦相互作用。

• 201种主要药物的相互作用
• 245种中等程度的药物相互作用
• 32种次要药物相互作用

在数据库中显示可能与阿扎那韦相互作用的所有药物。

检查互动

输入药物名称以检查与atazanavir的相互作用。

最常检查的互动

查看阿扎那韦和下列药物的相互作用报告。

• 乙酰水杨酸（阿司匹林）
• 雄激素（睾丸激素）
• 浓缩钙（碳酸钙）
• Celexa（西酞普兰）
• 铜（葡萄糖酸铜）
• 依法韦仑
• 法莫韦（泛昔洛韦）
• Folinic-Plus（多种维生素）
• K-Phos Original（磷酸钾）
• 拉米夫定
• 镁卡（天门冬氨酸镁）
• 二甲双胍
• 尼莫地平
• 奥美拉唑
• 普拉达沙（达比加群）
• 槲皮素（生物类黄酮）
• 雷格列韦
• 利托那韦
• 思乐康（喹硫平）
• 大豆卵磷脂（卵磷脂）
• 替诺福韦
• Truvada（恩曲他滨/替诺福韦）
• 维生素B2（核黄素）
• 维生素B6（吡rid醇）
• 维生素C（抗坏血酸）
• 维生素D3（胆钙化固醇）
• 维生素K（植物二酮）
• 锌（硫酸锌）

阿扎那韦醇/食物相互作用

阿扎那韦与酒精/食物有3种相互作用

阿扎那韦病毒相互作用

与阿扎那韦有8种疾病相互作用，包括：

• 心脏传导阻滞
• 肾结石症
• 肾功能不全
• 血友病
• 肝病
• 北大
• 高血糖症
• 高脂血症

药物状态

• 可用性 仅处方
• 怀孕和哺乳 现有风险数据
• CSA时间表* 不是管制药物
• 审批历史 FDA的药物史

相关药物

• 特鲁瓦达
• Isentress
• 苏斯蒂瓦
• 完成
• Epzicom
• Emtriva
• Atripla

美国日本医生

Heather Benjamin MD

经验：11-20年

Heather Benjamin MD

经验：11-20年

Suzanne Reitz MD

经验：11-20年

Heather Miske DO

经验：11-20年

Heather Miske DO

经验：11-20年

渡邊剛

经验：21年以上

渡邊剛

经验：21年以上

宮崎総一郎 中部大学特聘教授

经验：21年以上

百村伸一 教授

经验：21年以上

百村伸一 教授

经验：21年以上

临床试验

• 评估接受同种异体SCT（COSI）AML和MD的成年人结果影响的治疗试验
• 犬类气味诊断（KDOG1）的乳腺癌诊断（KDOG1）
• 结直肠癌患者和健康对照组中的挥发性有机化合物（VOC）谱。
• 癌症，营养和味觉（CANUT-1）
• 一项关于使用短信提醒使用Palbociclib的研究
• NAB-甲氟甲酰胺和alpelisib用于用PIK3CA或PTEN改变的蒽环类药物治疗难治性三重阴性乳腺癌
• 对患有晚期恶性肿瘤受试者的牛thotinib的研究
• 现代疗法治疗的癌症患者的血液，唾液和尿液的拉曼光谱的临床研究
• 与化学疗法和预防冰水浸入指甲色素沉着相关的指甲变化（Nipper）
• 曲妥珠单抗生物仿制药（Samfenet®）加上HER2阳性实体瘤（BIOS-HER）患者的医师选择（TPC）的治疗